Immuron Granted US Patent for NASH Treatment
November 15, 2017 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...
Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
August 18, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, is issuing this press release to...
Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
June 13, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., June 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and...
Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update
May 15, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., May 15, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
April 25, 2017 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., April 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin...
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
April 18, 2017 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., April 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Exalenz Bioscience (TASE:EXEN),...
Galectin Therapeutics Issues Statement Regarding GALTW and GALTU
March 23, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., March 23, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that trading will be...
Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis
October 07, 2016 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial
August 25, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announces interim results from an...